Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

Biochemical Pharmacology

Volumn 97, Issue 4, 2015, Pages 388-398

  Terry, Alvin V ^a   Callahan, Patrick M ^a   Hernandez, Caterina M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

's disease; Alzheimer; Cholinergic; Memory; Mild Cognitive Impairment; Schizophrenia

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYL 3 ISOXAZOLYL)UREA; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ABT 107; ALTINICLINE; AR R 1779; AVL 3288; AZD 1446; BRADANICLINE; BUNGAROTOXIN RECEPTOR; COTININE; ENCENICLINE; GALANTAMINE; GENISTEIN; ISPRONICLINE; JNJ 39393406; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NS 1738; NS 9283; POZANICLINE; RG 3487; SAZETIDINE A; SEN 12333; SOFINICLINE; TEBANICLINE; TROPISETRON; UNCLASSIFIED DRUG; VARENICLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; LIGAND;

AGING; ALLOSTERISM; ALZHEIMER DISEASE; ATTENTION; ATTENTION DEFICIT DISORDER; DRUG EFFECT; DRUG REPOSITIONING; EPISODIC MEMORY; EXECUTIVE FUNCTION; HUMAN; MENTAL DETERIORATION; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECOGNITION; REFERENCE MEMORY; REVIEW; SCHIZOPHRENIA; SPATIAL LEARNING; STATE DEPENDENT LEARNING; WORKING MEMORY; DRUG DEVELOPMENT; MENTAL DISORDERS; METABOLISM;

CHOLINERGIC AGENTS; DRUG DISCOVERY; LIGANDS; MENTAL DISORDERS; RECEPTORS, NICOTINIC;

EID: 84943357229     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.07.027     Document Type: Review

References (191)

1. S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, and et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat Rev Drug Discov. 9 2010 203 214
2. T.R. Insel, and B.J. Sahakian Drug research: a plan for mental illness Nature 483 2012 269
3. D.J. Chandler Something's got to give: psychiatric disease on the rise and novel drug development on the decline Drug Discov. Today 18 2013 202 206
4. A.G. Reaume Drug repurposing through nonhypothesis driven phenotypic screening Drug Discov. Today Ther. Strateg. 8 2011 85 88
5. G.M. Maggiora The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs J Comput Aided Mol Des 25 2011 699 708
6. J.L. Medina-Franco, M.A. Giulianotti, G.S. Welmaker, and R.A. Houghten Shifting from the single to the multitarget paradigm in drug discovery Drug Discov. Today. 18 2013 495 501
7. M.B. Youdim, and J.J. Buccafusco Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders Trends Pharmacol. Sci. 26 2005 27 35
8. T.T. Ashburn, and K.B. Thor Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683
9. A. Merino, A.K. Bronowska, D.B. Jackson, and D.J. Cahill Drug profiling: knowing where it hits Drug. Discov. Today 15 2010 749 756
10. L. Descarries, V. Gisiger, and M. Steriade Diffuse transmission by acetylcholine in the CNS Prog. Neurobiol. 53 1997 603 625
11. E.X. Albuquerque, E.F. Pereira, M. Alkondon, and S.W. Rogers Mammalian nicotinic acetylcholine receptors: from structure to function Physiol. Rev. 89 2009 73 120
12. R. Freedman, M. Hall, L.E. Adler, and S. Leonard Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol. Psychiatry 38 1995 22 33
13. L. Burghaus, U. Schutz, U. Krempel, R.A. de Vos, E.N. Jansen Steur, A. Wevers, and et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients Brain Res. Mol. Brain Res. 76 2000 385 388
14. Z.Z. Guan, X. Zhang, R. Ravid, and A. Nordberg Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease J. Neurochem. 74 2000 237 243
15. C. Gotti, M. Moretti, A. Gaimarri, A. Zanardi, F. Clementi, and M. Zoli Heterogeneity and complexity of native brain nicotinic receptors Biochem. Pharmacol. 74 2007 1102 1111
16. D.S. McGehee, M.J. Heath, S. Gelber, P. Devay, and L.W. Role Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors Science 269 1995 1692 1696
17. K.T. Chang, and D.K. Berg Nicotinic acetylcholine receptors containing alpha7 subunits are required for reliable synaptic transmission in situ J. Neurosci. 19 1999 3701 3710
18. S. Hefft, S. Hulo, D. Bertrand, and D. Muller Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices J. Physiol. 515 Pt 3 1999 769 776
19. M.L. Messi, M. Renganathan, E. Grigorenko, and O. Delbono Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons FEBS lett. 411 1997 32 38
20. F. Berger, F.H. Gage, and S. Vijayaraghavan Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells J. Neurosci. Off. J. Soc. Neurosci. 18 1998 6871 6881
21. R.S. Bitner, W.H. Bunnelle, D.J. Anderson, C.A. Briggs, J. Buccafusco, P. Curzon, and et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways J. Neurosci. Off. J. Soc. Neurosci. 27 2007 10578 10587
22. R.S. Bitner, W.H. Bunnelle, M.W. Decker, K.U. Drescher, K.L. Kohlhaas, S. Markosyan, and et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease J. Pharmacol. Exp. Ther. 334 2010 875 886
23. W.R. Kem The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) Behav. Brain Res. 113 2000 169 181
24. E.D. Levin, F.J. McClernon, and A.H. Rezvani Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization Psychopharmacology 184 2006 523 539
25. E.D. Levin, and B.B. Simon Nicotinic acetylcholine involvement in cognitive function in animals Psychopharmacology 138 1998 217 230
26. N.R. Mirza, and I.P. Stolerman Nicotine enhances sustained attention in the rat under specific task conditions Psychopharmacology 138 1998 266 274
27. C. Puma, O. Deschaux, R. Molimard, and J.C. Bizot Nicotine improves memory in an object recognition task in rats Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol. 9 1999 323 327
28. K. Elrod, J.J. Buccafusco, and W.J. Jackson Nicotine enhances delayed matching-to-sample performance by primates Life Sci. 43 1988 277 287
29. J.J. Buccafusco, and W.J. Jackson Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys Neurobiol. Aging 12 1991 233 238
30. M.A. Prendergast, W.J. Jackson, A.V. Terry Jr., N.J. Kille, S.P. Arneric, M.W. Decker, and et al. Age-related differences in distractibility and response to methylphenidate in monkeys Cereb. Cortex 8 1998 164 172
31. H.K. White, and E.D. Levin Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease Psychopharmacology 143 1999 158 165
32. P.A. Newhouse, and M. Kelton Nicotinic systems in central nervous systems disease: degenerative disorders and beyond Pharm. Acta Helv. 74 2000 91 101
33. S.K. Min, I.W. Moon, R.W. Ko, and H.S. Shin Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers Psychopharmacology 159 2001 83 88
34. B. Sahakian, G. Jones, R. Levy, J. Gray, and D. Warburton The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type Br. J. Psychiatry J. Mental Sci. 154 1989 797 800
35. V. Kumari, and P. Postma Nicotine use in schizophrenia: the self medication hypotheses Neurosci. Biobehav. Rev. 29 2005 1021 1034
36. M.R. Picciotto, and M. Zoli Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease Front. Biosci. J. Virtual Lib. 13 2008 492 504
37. P. Newhouse, K. Kellar, P. Aisen, H. White, K. Wesnes, E. Coderre, and et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial Neurology 78 2012 91 101
38. D.K. Hatsukami, M. Grillo, P.R. Pentel, C. Oncken, and R. Bliss Safety of cotinine in humans: physiologic, subjective, and cognitive effects Pharmacol. Biochem. Behav. 57 1997 643 650
39. N.L. Benowitz Pharmacology of nicotine: addiction and therapeutics Annual Rev. Pharmacol. Toxicol. 36 1996 597 613
40. J.A. Rosecrans Nicotine as a discriminative stimulus to behavior: its characterization and relevance to smoking behavior NIDA Res. Monogr. 5 1979 8 69
41. S. Burgess, R. Zeitlin, and V. Echeverria Cotinine inhibits amyloid-β peptide neurotoxicity and oligomerization J. Clinic. Toxicol. S1 2011 6
42. J. Gao, B.-L. Adam, and A.V. Terry Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease Bioorg. Med. Chem. Lett. 24 2014 1472 1478
43. A.V. Terry, C.M. Hernandez, E.J. Hohnadel, K.P. Bouchard, and J.J. Buccafusco Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition CNS Drug Rev. 11 2005 229 252
44. V. Echeverria, R. Zeitlin, S. Burgess, S. Patel, A. Barman, G. Thakur, and et al. Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice J. Alzheimer's Dis. JAD 24 2011 817 835
45. S. Patel, J.A. Grizzell, R. Holmes, R. Zeitlin, R. Solomon, T.L. Sutton, and et al. Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice Front. Aging Neurosci. 6 2014 162
46. A.V. Terry Jr., J.J. Buccafusco, R.F. Schade, L. Vandenhuerk, P.M. Callahan, W.D. Beck, and et al. The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats Biochem. Pharmacol. 83 2012 941 951
47. J.J. Buccafusco, and A.V. Terry Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists Biochem. Pharmacol. 78 2009 852 862
48. J.A. Grizzell, M. Mullins, A. Iarkov, A. Rohani, L.C. Charry, and V. Echeverria Cotinine reduces depressive-like behavior and hippocampal vascular endothelial growth factor downregulation after forced swim stress in mice Behav. Neurosci. 128 2014 713 721
49. S.P. Arneric, J.P. Sullivan, C.A. Briggs, D. Donnelly-Roberts, D.J. Anderson, J.L. Raszkiewicz, and et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization J. Pharmacol. Exp. Ther. 270 1994 310 318
50. N.D. Cosford, L. Bleicher, A. Herbaut, J.S. McCallum, J.M. Vernier, H. Dawson, and et al. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors J.Med. Chem. 39 1996 3235 3237
51. G. Mullen, J. Napier, M. Balestra, T. DeCory, G. Hale, J. Macor, and et al. (-)-Spiro[1-azabicyclo[2. 2. 2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor J. Med. Chem. 43 2000 4045 4050
52. G.W. Arendash, G.J. Sengstock, P.R. Sanberg, and W.R. Kem Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21 Brain Res. 674 1995 252 259
53. C.A. Briggs, D.J. Anderson, J.D. Brioni, J.J. Buccafusco, M.J. Buckley, J.E. Campbell, and et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo Pharmacol. Biochem. Behav. 57 1997 231 241
54. M.W. Decker, J.D. Brioni, J.P. Sullivan, M.J. Buckley, R.J. Radek, J.L. Raszkiewicz, and et al. S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization J. Pharmacol. Exp. Ther. 270 1994 319 328
55. S.M. Ferguson, J.D. Brodkin, G.K. Lloyd, and F. Menzaghi Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression Psychopharmacology 152 2000 295 303
56. E.D. Levin, C. Bettegowda, J. Blosser, and J. Gordon AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats Behavioural Pharmacol. 10 1999 675 680
57. M.A. Prendergast, W.J. Jackson, A.V. Terry Jr., M.W. Decker, S.P. Arneric, and J.J. Buccafusco Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys Psychopharmacology 136 1998 50 58
58. J.S. Schneider, J.P. Tinker, M. Van Velson, F. Menzaghi, and G.K. Lloyd Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys J. Pharmacol. Exp. Ther. 290 1999 731 739
59. K.E. Stevens, W.R. Kem, V.M. Mahnir, and R. Freedman Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice Psychopharmacology 136 1998 320 327
60. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth, and et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch. Gen. Psychiatry 63 2006 630 638
61. A. Potter, J. Corwin, J. Lang, M. Piasecki, R. Lenox, and P.A. Newhouse Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology 142 1999 334 342
62. T.E. Wilens, J. Biederman, T.J. Spencer, J. Bostic, J. Prince, M.C. Monuteaux, and et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder Am. J. Psychiatry 156 1999 1931 1937
63. M.W. Decker, A.W. Bannon, P. Curzon, K.L. Gunther, J.D. Brioni, M.W. Holladay, and et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys J. Pharmacol. Exp. Ther. 283 1997 247 258
64. T.A. Hauser, A. Kucinski, K.G. Jordan, G.J. Gatto, S.R. Wersinger, R.A. Hesse, and et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia Biochem. Pharmacol. 78 2009 803 812
65. M.C. Obinu, M. Reibaud, J.M. Miquet, M. Pasquet, and T. Rooney Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26 2002 913 918
66. J. Prickaerts, N.P. van Goethem, R. Chesworth, G. Shapiro, F.G. Boess, C. Methfessel, and et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors Neuropharmacology 62 2012 1099 1110
67. T.L. Wallace, P.M. Callahan, A. Tehim, D. Bertrand, G. Tombaugh, S. Wang, and et al. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents J. Pharmacol. Exp. Ther. 336 2011 242 253
68. R.J. Radek, H.M. Robb, K.E. Stevens, M. Gopalakrishnan, and R.S. Bitner Effects of the novel alpha7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization J. Pharmacol. Exp. Ther. 343 2012 736 745
69. H. Rollema, M. Hajos, P.A. Seymour, R. Kozak, M.J. Majchrzak, V. Guanowsky, and et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition Biochem. Pharmacol. 78 2009 813 824
70. S. Sadigh-Eteghad, M. Talebi, J. Mahmoudi, S. Babri, and D. Shanehbandi Selective activation of alpha7 nicotinic acetylcholine receptor by PHA-543613 improves Abeta25-35-mediated cognitive deficits in mice Neuroscience 298 2015 81 93
71. G.C. Dunbar, R.V. Kuchibhatla, and G. Lee A randomized double-blind study comparing 25 and 50mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment J. Psychopharmacol. 25 2011 1020 1029
72. L. Frolich, T. Ashwood, J. Nilsson, and G. Eckerwall Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study Alzheimer's Dis. JAD 24 2011 363 374
73. R.A. Lenz, Y.L. Pritchett, S.M. Berry, D.A. Llano, S. Han, D.A. Berry, and et al. Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease Alzheimer Dis. A. Disorders 2015
74. T.L. Wallace, and R.H. Porter Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease Biochem. Pharmacol. 82 2011 891 903
75. W.J. Deardorff, A. Shobassy, and G.T. Grossberg Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication Expert Rev. Neurother. 15 2015 7 17
76. T.L. Wallace, and D. Bertrand Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex Biochem. Pharmacol. 85 2013 1713 1720
77. V. Parikh, J. Ji, M.W. Decker, and M. Sarter Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling J. Neurosci. Off. J. Soc. Neurosci. 30 2010 3518 3530
78. M. Huang, A.R. Felix, S. Kwon, D. Lowe, T. Wallace, L. Santarelli, and et al. The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release Psychopharmacology 231 2014 2199 2210
79. P.M. Callahan, and A.V. Terry Jr. Attention Handbook of Experimental Pharmacology 228 2015 Springer International Publishing Switzerland 161 189
80. W.M. Howe, J. Ji, V. Parikh, S. Williams, E. Mocaer, C. Trocme-Thibierge, and et al. Enhancement of Attentional Performance by Selective Stimulation of Alpha4beta2(∗) Nachrs: Underlying Cholinergic Mechanisms 35 2010 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 1391 1401
81. J. McGaughy, M.W. Decker, and M. Sarter Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats Psychopharmacology 144 1999 175 182
82. E.G. Mohler, S.R. Franklin, L.E. Rueter, G.B. Fox, M.W. Decker, and K.E. Browman ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects Pharmacol. Biochem. Behav. 95 2010 146 157
83. J.W. Young, K. Finlayson, C. Spratt, H.M. Marston, N. Crawford, J.S. Kelly, and et al. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor 29 2004 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 891 900
84. E. Hoyle, R.F. Genn, C. Fernandes, and I.P. Stolerman Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task Psychopharmacology 189 2006 211 223
85. J.W. Young, N. Crawford, J.S. Kelly, L.E. Kerr, H.M. Marston, C. Spratt, and et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol. 17 2007 145 155
86. A.H. Rezvani, E. Kholdebarin, F.H. Brucato, P.M. Callahan, D.A. Lowe, and E.D. Levin Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats Prog.Neuro-psychopharmacol. Biol. Psychiatry 33 2009 269 275
87. T.L.C.G. Wallace-Boone, H. Dao, D.A. Lowe, R. Porter, and L. Santarelli R3487/MEM3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques Soc. Neurosci. 2009
88. A. Shiina, Y. Shirayama, T. Niitsu, T. Hashimoto, T. Yoshida, T. Hasegawa, and et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia Ann. Gen. Psychiatry 9 2010 27
89. A.J. Grottick, and G.A. Higgins Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task Behav. Brain Res. 117 2000 197 208
90. J.W. Young, J.M. Meves, and M.A. Geyer Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test Behav. Brain Res. 240 2013 119 133
91. G. Apostol, W. Abi-Saab, C.J. Kratochvil, L.A. Adler, W.Z. Robieson, L.M. Gault, and et al. Efficacy and safety of the novel alpha(4) beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study Psychopharmacology 219 2012 715 725
92. E.E. Bain, W. Robieson, Y. Pritchett, T. Garimella, W. Abi-Saab, G. Apostol, and et al. A randomized, Double-blind, Placebo-controlled Phase 2 Study of Alpha4beta2 Agonist Abt-894 in Adults with Adhd 38 2013 Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology 405 413
93. A.S. Potter, G. Dunbar, E. Mazzulla, D. Hosford, and P.A. Newhouse AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults Biol. Psychiatry 75 2014 207 214
94. A. Jucaite, J. Ohd, A.S. Potter, J. Jaeger, P. Karlsson, K. Hannesdottir, and et al. A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2∗nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder Psychopharmacology 231 2014 1251 1265
95. M.F. Green, and D.L. Braff Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications Biol. Psychiatry 49 2001 374 384
96. L.E. Adler, A. Olincy, M. Waldo, J.G. Harris, J. Griffith, K. Stevens, and et al. Schizophrenia, sensory gating, and nicotinic receptors Schizophr. Bull. 24 1998 189 202
97. R. Freedman, and S. Leonard Genetic linkage to schizophrenia at chromosome 15q14 Am. J. Med. Genet. 105 2001 655 657
98. D. Gothelf, N. Soreni, R.P. Nachman, S. Tyano, Y. Hiss, O. Reiner, and et al. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol. 10 2000 389 395
99. A. Olincy, D.A. Young, and R. Freedman Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers Biol. Psychiatry 42 1 1997 1 5
100. K.E. Stevens, and K.D. Wear Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models Pharmacol. Biochem. Behav. 57 1997 869 874
101. L.E. Adler, L.D. Hoffer, A. Wiser, and R. Freedman Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am. J. Psychiatry 150 1993 1856 1861
102. K. Hashimoto, M. Iyo, R. Freedman, and K.E. Stevens Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors Psychopharmacology 183 2005 13 19
103. K. Koike, K. Hashimoto, N. Takai, E. Shimizu, N. Komatsu, H. Watanabe, and et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia Schizophr. Res. 76 2005 67 72
104. X.Y. Zhang, L. Liu, S. Liu, X. Hong, C. Chen da, M.H. Xiu, and et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia Am. J. Psychiatry 169 2012 974 981
105. D.L. Braff, M.A. Geyer, and N.R. Swerdlow Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies Psychopharmacology 156 2001 234 258
106. V. Kumari, W. Soni, and T. Sharma Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia Hum. Psychopharmacol. 16 2001 321 326
107. L.E. Hong, I. Wonodi, J. Lewis, and G.K. Thaker Nicotine Effect on Prepulse Inhibition and Prepulse Facilitation in Schizophrenia Patients 33 2008 Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology 2167 2174
108. T.P. George, A. Termine, K.A. Sacco, T.M. Allen, E. Reutenauer, J.C. Vessicchio, and et al. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms Schizophr. Res. 87 2006 307 315
109. P.M. Callahan, A.V. Terry Jr., and A. Tehim Effects of the nicotinic alpha7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats Psychopharmacology 231 2014 3695 3706
110. C. Ghiron, S.N. Haydar, S. Aschmies, H. Bothmann, C. Castaldo, G. Cocconcelli, and et al. Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl) pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914) J. Med. Chem. 53 2010 4379 4389
111. S. Kohnomi, K. Suemaru, M. Goda, T. Choshi, S. Hibino, H. Kawasaki, and et al. Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats Brain Res. 1353 2010 152 158
112. R. Roncarati, C. Scali, T.A. Comery, S.M. Grauer, S. Aschmi, H. Bothmann, and et al. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders J. Pharmacol. Exp. Ther. 329 2009 459 468
113. N.R. Swerdlow, G.A. Light, K.S. Cadenhead, J. Sprock, M.H. Hsieh, and D.L. Braff Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function Arch. Gen. Psychiatry 63 2006 1325 1335
114. R.A. Rabin, K.A. Sacco, and T.P. George Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status Schizophr. Res. 114 2009 91 97
115. A. Aleman, R. Hijman, E.H. de Haan, and R.S. Kahn Memory impairment in schizophrenia: a meta-analysis Am. J. Psychiatry 156 1999 1358 1366
116. C. Ranganath, M.J. Minzenberg, and J.D. Ragland The cognitive neuroscience of memory function and dysfunction in schizophrenia Biol. Psychiatry 64 2008 18 25
117. P. Pichat, O.E. Bergis, J.P. Terranova, A. Urani, C. Duarte, V. Santucci, and S.S.R. et al 1 80711, a Novel Selective Alpha7 Nicotinic Receptor Partial Agonist: (ii) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia 32 2007 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 17 34
118. M.N. de Lima, D.C. Laranja, E. Bromberg, R. Roesler, and N. Schroder Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats Behav. Brain Res. 156 2005 139 143
119. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of Ketamine in Normal and Schizophrenic Volunteers 25 2001 Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology 455 467
120. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar, and et al. Ketamine-induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-free Schizophrenics 17 1997 Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology 141 150
121. K. Hashimoto, T. Ishima, Y. Fujita, M. Matsuo, T. Kobashi, M. Takahagi, and et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR 180711 Biol. Psychiatry 63 2008 92 97
122. C.E. Cannon, V. Puri, J.A. Vivian, M.S. Egbertson, D. Eddins, and J.M. Uslaner The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys Neuropharmacology 64 2013 191 196
123. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson, and et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia Am. J. Psychiatry 165 2008 1040 1047
124. J.A. Lieberman, G. Dunbar, A.C. Segreti, R.R. Girgis, F. Seoane, J.S. Beaver, and et al. A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (tc-5619) for Cognitive Enhancement in Schizophrenia 38 2013 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 968 975
125. S.H. Preskorn, M. Gawryl, N. Dgetluck, M. Palfreyman, L.O. Bauer, and D.C. Hilt Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia J. Psychiatr Pract. 20 2014 12 24
126. D. Umbricht, R.S. Keefe, S. Murray, D.A. Lowe, R. Porter, G. Garibaldi, and et al. A Randomized, Placebo-controlled Study Investigating the Nicotinic Alpha7 Agonist, Rg3487, for Cognitive Deficits in Schizophrenia 39 2014 Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 1568 1577
127. M. Noroozian, S. Ghasemi, S.M. Hosseini, A. Modabbernia, M.R. Khodaie-Ardakani, O. Mirshafiee, and et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia Psychopharmacology 228 2013 595 602
128. D. Bertrand, and M. Gopalakrishnan Allosteric modulation of nicotinic acetylcholine receptors Biochem. Pharmacol. 74 2007 1155 1163
129. M. Grupe, M. Grunnet, J.F. Bastlund, and A.A. Jensen Targeting alpha4beta2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach Basic Clinic. Pharmacol. Toxicol. 116 2015 187 200
130. D.B. Timmermann, K. Sandager-Nielsen, T. Dyhring, M. Smith, A.M. Jacobsen, E.O. Nielsen, and et al. Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors Br. J. Pharmacol. 167 2012 164 182
131. C.H. Lee, C. Zhu, J. Malysz, T. Campbell, T. Shaughnessy, P. Honore, and et al. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain Biochem. Pharmacol. 82 2011 959 966
132. C.Z. Zhu, C.L. Chin, N.R. Rustay, C. Zhong, J. Mikusa, P. Chandran, and et al. Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats Biochem. Pharmacol. 82 2011 967 976
133. F. Rode, G. Munro, D. Holst, E.O. Nielsen, K.B. Troelsen, D.B. Timmermann, and et al. Positive allosteric modulation of alpha4beta2 nAChR agonist induced behaviour Brain Res. 1458 2012 67 75
134. M. Grupe, M. Grunnet, B. Laursen, and J.F. Bastlund Neuropharmacological modulation of the P3-like event-related potential in a rat two-tone auditory discrimination task with modafinil and NS9283, a positive allosteric modulator of alpha4beta2 nAChRs Neuropharmacology 79 2014 444 455
135. E.G. Mohler, S.R. Franklin, and L.E. Rueter Discriminative-stimulus effects of NS9283, a nicotinic α4β2∗positive allosteric modulator, in nicotine-discriminating rats Psychopharmacology 231 2014 67 74
136. D.B. Timmermann, J.H. Gronlien, K.L. Kohlhaas, E.O. Nielsen, E. Dam, T.D. Jorgensen, and et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo J. Pharmacol. Exp. Ther. 323 2007 294 307
137. H.J. Ng, E.R. Whittemore, M.B. Tran, D.J. Hogenkamp, R.S. Broide, T.B. Johnstone, and et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators Proceedings of the National Academy of Sciences of the United States of America 104 2007 8059 8064
138. A. Nikiforuk, T. Kos, A. Potasiewicz, and P. Popik Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol. 2015
139. D.J. Hogenkamp, T.A. Ford-Hutchinson, W.Y. Li, E.R. Whittemore, R.F. Yoshimura, M.B. Tran, and et al. Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of alpha7 nicotinic acetylcholine receptors J. Med. Chem. 56 2013 8352 8365
140. J. Dunlop, T. Lock, B. Jow, F. Sitzia, S. Grauer, F. Jow, and et al. Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide) J. Pharmacol. Exp. Ther. 328 2009 766 776
141. P.M. Callahan, E.J. Hutchings, N.J. Kille, J.M. Chapman, and A.V. Terry Jr. Positive allosteric modulator of alpha7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates Neuropharmacology 67 2013 201 212
142. K.L. Kohlhaas, R.S. Bitner, M. Gopalakrishnan, and L.E. Rueter Effects of alpha7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis Psychopharmacology. 220 2012 823 833
143. S.L. McLean, N.F. Idris, B. Grayson, D.F. Gendle, C. Mackie, A.S. Lesage, and et al. PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats J. Psychopharmacol. 26 2012 1265 1270
144. S. Sahdeo, T. Wallace, R. Hirakawa, F. Knoflach, D. Bertrand, H. Maag, and et al. Characterization of RO5126946, a Novel α7 nicotinic acetylcholine receptor-positive allosteric modulator J Pharmacol Exp Ther. 350 2014 455 468
145. R.S. Hurst, M. Hajos, M. Raggenbass, T.M. Wall, N.R. Higdon, J.A. Lawson, and et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization J. Neurosci. Off. J. Soc. Neurosci. 25 2005 4396 4405
146. K.E. Stevens, L. Zheng, K.L. Floyd, and J.A. Stitzel Maximizing the effect of an alpha7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits Brain Res. 1611 2015 8 17
147. T. Dinklo, H. Shaban, J.W. Thuring, H. Lavreysen, K.E. Stevens, L. Zheng, and et al. Characterization of 2-[[4-fluoro-3-(trifluoromethyl) phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor J. Pharmacol. Exp. Ther. 336 2011 560 574
148. G. Winterer, J. Gallinat, J. Brinkmeyer, F. Musso, J. Kornhuber, N. Thuerauf, and et al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study Neuropharmacology 64 2013 197 204
149. R. Quirion, A. Wilson, W. Rowe, I. Aubert, J. Richard, H. Doods, and et al. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired J. Neurosci. Off. J. Soc. Neurosci. 15 1995 1455 1462
150. T.M. Powledge Nicotine as therapy PLoS Biol. 2 2004 e404
151. R.W. Gould, P.K. Garg, S. Garg, and M.A. Nader Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history Neuropharmacology 64 2013 479 488
152. R.C. Smith, J.P. Lindenmayer, J.M. Davis, J. Cornwell, K. Noth, S. Gupta, and et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder Schizophr. Res. 110 2009 149 155
153. S.Y. Kim, S.H. Choi, H. Rollema, E.M. Schwam, T. McRae, S. Dubrava, and I.I. et al. Phase crossover trial of varenicline in mild-to-moderate Alzheimer's disease Dement. Geriatr. Cogni. Disorders 37 2014 232 245
154. J.C. Shim, D.U. Jung, S.S. Jung, Y.S. Seo, D.M. Cho, J.H. Lee, and et al. Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: a Randomized Double-blind Placebo-controlled Trial 37 2012 Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology 660 668
155. D.L. Donnelly-Roberts, I.C. Xue, S.P. Arneric, and J.P. Sullivan In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418 Brain Res. 719 1996 36 44
156. J.J. Buccafusco, A.V. Terry, M.W. Decker, and M. Gopalakrishnan Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys Biochem. Pharmacol. 74 2007 1202 1211
157. D.L. Donnelly-Roberts, P.S. Puttfarcken, T.A. Kuntzweiler, C.A. Briggs, D.J. Anderson, J.E. Campbell, and et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization J. Pharmacol Exp Ther. 285 1998 777 786
158. M.C. Rowbotham, A. Arslanian, W. Nothaft, W.R. Duan, A.E. Best, Y. Pritchett, and et al. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain Pain 153 2012 862 868
159. A.A. Mazurov, L. Miao, B.S. Bhatti, J.P. Strachan, S. Akireddy, S. Murthy, and et al. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3. 3. 0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders J. Med. Chem. 55 2012 9181 9194
160. K. Szeliga, K. Jordan, T. Hauser, A. Mazurov, D. Yohannes, A. Rezvani, and et al. AZD1446 (TC -6683), a novel alpha4beta2 nAChR agonist with cognitive-enhancing properties Soc. Neurosci. 2012
161. T. Bordia, M. McGregor, R.L. Papke, M.W. Decker, J.M. McIntosh, and M. Quik The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions Exp. Neurol. 263 2015 277 284
162. M. Van Kampen, K. Selbach, R. Schneider, E. Schiegel, F. Boess, and R. Schreiber AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors Psychopharmacology 172 2004 375 383
163. N. Pitsikas, and F. Borsini Different effects of tropisetron and ondansetron in learning and memory paradigms Pharmacol. Biochem. Behav. 56 1997 571 576
164. P. Spilman, O. Descamps, O. Gorostiza, C. Peters-Libeu, K.S. Poksay, A. Matalis, and et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model Brain Res. 1551 2014 25 44
165. J. Sawyer, E.L. Eaves, C.J. Heyser, and S. Maswood Tropisetron, a 5-HT(3) receptor antagonist, enhances object exploration in intact female rats Behav. Pharmacol. 23 2012 806 809
166. C.M. Hernandez, D.A. Gearhart, V. Parikh, E.J. Hohnadel, L.W. Davis, M.L. Middlemore, and et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats J. Pharmacol. Exp. Ther. 316 2006 679 694
167. E. Hohnadel, K. Bouchard, and A.V. Terry Jr. Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats Neuropharmacology 52 2007 542 551
168. D.K. Williams, J. Wang, and R.L. Papke Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations Biochem. Pharmacol. 82 2011 915 930
169. J.P. Sullivan, D. Donnelly-Roberts, C.A. Briggs, D.J. Anderson, M. Gopalakrishnan, I.C. Xue, and et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties J. Pharmacol. Exp. Ther. 283 1997 235 246
170. L.E. Rueter, D.J. Anderson, C.A. Briggs, D.L. Donnelly-Roberts, G.A. Gintant, M. Gopalakrishnan, and et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders CNS Drug Rev. 10 2004 167 182
171. E.T. Menze, A. Esmat, M.G. Tadros, A.B. Abdel-Naim, and A.E. Khalifa Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties PLoS One 10 February (2) 2015 e0117223
172. J.J. Buccafusco, and A.V. Terry Jr. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Invited Minireview Life Sci. 72 2003 2931 2942
173. J.J. Buccafusco, and A.V. Terry Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists Biochem. Pharmacol. 78 2009 852 862
174. A.V. Terry, P.M. Callahan, and D. Bertrand R-(+) - and S-(-) - Isomers of Cotinine Augment Cholinergic Responses in vitro and in vivo J. Pharmacol. Exp. Ther. 352 2015 405 418
175. A.H. Rezvani, M. Cauley, Y. Xiao, K.J. Kellar, and E.D. Levin Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats Psychopharmacology 226 1 2013 35 43
176. G. Cucchiaro, Y. Xiao, A. Gonzalez-Sulser, and K.J. Kellar Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug Anesthesiology 109 3 2008 512 519
177. J.R. Turner, L.M. Castellano, and J.A. Blendy Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior J. Pharmacol. Exp. Ther. 334 2 2010 665 672
178. P. Lippiello, S.R. Letchworth, G.J. Gatto, V.M. Traina, and Bencherif M. Ispronicline a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties J. Mol. Neurosci. 30 1-2 2006 19 20
179. G.J. Gatto, G.A. Bohme, W.S. Caldwell, S.R. Letchworth, V.M. Traina, M.C. Obinu, M. Laville, M. Reibaud, L. Pradier, G. Dunbar, and M. Bencherif TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects CNS Drug Rev. 10 Summer (2) 2004 147 166
180. V. Kumari, and P. Postma Nicotine use in schizophrenia: the self medication hypotheses Neurosci. Biobehav. Rev. 29 6 2005 1021 1034
181. T.R. Stevens, S.R. Krueger, R.M. Fitzsimonds, and M.R. Picciotto Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and l-type calcium channel inactivation J. Neurosci. 31 2003 10093 10099
182. J. Kawamata, and S. Shimohama Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases J. Alzheimer's Dis. 24 Suppl. 2 2011 95 109
183. F. Serres, and S.L. Carney Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor Brain Res. 1101 1 2006 36 42
184. E. Formaggio, F. Fazzini, A.C. Dalfini, M. Di Chio, C. Cantù, I. Decimo, and et al. Nicotine increases the expression of neurotrophin receptor tyrosine kinase receptor A in basal forebrain cholinergic neurons Neuroscience 166 2 2010 580 589
185. J.D. Brioni, M.W. Decker, J.P. Sullivan, and S.P. Arneric The pharmacology of (-)-nicotine and novel cholinergic channel modulators Ad.v Pharmacol. 37 1997 153 214
186. M.J. Marks, P. Whiteaker, J. Calcaterra, J.A. Stitzel, A.E. Bullock, S.R. Grady, and et al. Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit J. Pharmacol. Exp. Ther. 289 2 1999 1090 1103
187. P.B. Sargent The diversity of neuronal nicotinic acetylcholine receptors Annual Rev. Neurosci. 16 1993 403 443
188. S. Wonnacott Presynaptic nicotinic ACh receptors Trends Neurosci. 20 2 1997 92 98
189. E.D. Levin E.D. Levin, Nicotinic Receptors in the Nervous System 2001 CRC Press Boca Raton
190. J.A. Dani, and D. Bertrand Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system Annu. Rev. Pharmacol. Toxicol. 47 2007 699 729
191. A. Taly, P.J. Corringer, D. Guedin, P. Lestage, and J.P. Changeux Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discov. 8 9 2009 733 750